GenScript Life Science Research Grant Program (Global Pioneer Grant, Rising Star Grant, AI Drug Discovery Frontier Grant, Spark Pitch Grant)

GenScript Life Science Research Grant Program (Global Pioneer Grant, Rising Star Grant, AI Drug Discovery Frontier Grant, Spark Pitch Grant) is sponsored by GenScript. This global initiative supports life science innovation, including projects that contribute to critical areas of life science research such as AI-drug discovery, antibody development, cell and gene therapy, vaccines, diagnostics, and biologics.

## What Is GenScript LSRG? The **GenScript Life Science Research Grant** (GenScript LSRG) is the **global initiative for life science innovation**, providing **$1. 5 million in annual funding** to support researchers shaping the future of life science.

Many promising ideas face real challenges, not because they lack merit, but because researchers may have limited access to funding, infrastructure, and the right scientific ecosystem.

By combining **funding, scientific expertise**, and **global ecosystem access**, GenScript LSRG helps ideas develop, scale, and move toward real-world impact whether you're advancing **AI-powered drug discovery, antibody engineering, cell and gene therapies, vaccines, diagnostics, biologics**, or other research areas.

Supports ambitious, high-impact innovation with the potential to drive meaningful advances in global health and life sciences. ​ The **Global Pioneer Grant** supports bold ideas grounded in strong scientific merit and real-world relevance, helping innovations progress toward broader impact. Supports emerging innovators who are establishing their path and shaping the next generation of scientific progress.

​ The **Rising Star Grant** is designed for researchers and innovators at earlier stages of their career or new directions of their work, those building momentum and bringing fresh perspectives to life science. Designed for innovators applying artificial intelligence to accelerate the discovery and development of new therapeutics.

The **AI Drug Discovery Frontier Grant** supports innovators that use AI, machine learning, computational modeling, or data-driven platforms to advance key stages of drug discovery. This tier follows an offline, event-based application and selection process. Online applications are not accepted.

Eligibility, event details, and award announcements will be shared separately. #### Technical Support & Solutions Access to GenScript expertise, technologies, and solutions to support project execution. #### Networking Opportunities Connect with scientific peers, industry experts, and broader research communities through conferences and GenScript hosted events.

From application to impact, we support you every step of the way. Submit your research proposal and project needs during the application window. Applications are evaluated through a structured review process based on scientific merit, innovation, feasibility, and potential for impact.

Selected applicants are announced as GenScript LSRG awardees and receive next-step guidance from the GenScript team. Awardees complete the onboarding process and begin leveraging their grants, gaining access to funding, scientific resources, and the broader GenScript LSRG ecosystem.

As projects progress, GenScript continues to support awardees with technical expertise and opportunities for visibility and recognition, helping ideas move forward and reach greater impact.

**Path to Your GenScript Life Science Research Grant** ## Researchers We’ve Supported “GenScript LSRG enabled us to do the breadth of experiments we needed, with all the plasmids and proteins required to get our company from idea to _in vitro_ and _ex vivo_ proof of concept for our immune reprogramming medicine” “This grant has allowed Ikarovec to expand our in vivo anti-fibrotic evaluation, which in turn will help complete a full data package suitable for clinical development.

” "The BLI assays performed at GenScript allow us to show that our in-silico protein design process is able to design binders at very high success probability. We can now use the results of this assay to guide our designs in the following cellular assays." “Thanks to the GenScript LSRG grant, we could expand our repertoire of de novo synthesis to 100 synthetic sequences, and have them all synthesized and shipped to us.

An endeavor otherwise not possible for an academic lab. ” “This funding is enabling the development of a critical research tool that I hope will generate key preliminary data to support further studies and unlock additional opportunities for larger-scale funding to advance this work.

” "This GenScript LSRG grant provides me with the funding to kick-start a high-risk, high-reward research project that is at the forefront of cancer immunotherapy. GenScript’s high quality and rapid plasmid, mRNA and AAV services has drastically reduced the time it has taken to translate ideas into real-world feasibility data which will attract further funding and development."

Adam Contreras Biostone Animal Health LLC Diagnostics Changyang Linghu University of Michigan Other Christopher Wood MOMM Diagnostics GmbH Diagnostics Chung-I Chang Academia Sinica Plant Sriramya Ayyagari University of Illinois at Chicago Gene and Cell Therapy Giulio Chiesa University of Toronto Gene and Cell Therapy Giuseppe A.

Sautto Cleveland Clinic Florida Research and Innovation Center Vaccine Development Guo Luo Stanford University School of Medicine Gene and Cell Therapy Harinad Maganti Canadian Blood Services Gene and Cell Therapy JINGXUAN GUO Dr. David Schaffer lab Gene and Cell Therapy Kevin Sek The University of Melbourne Gene and Cell Therapy Lamberto Torralba-Rag Oslo universitetssykehus HF Gene and Cell Therapy Laura Vaux Ikarovec Limited Gene and Cell Therapy Mark Sellmyer University of Pennsylvania Diagnostics Nazia Samudh University of the Witwatersrand Vaccine Development Oleg Gang Columbia University Other Peter Pushko Medigen, Inc. Vaccine Development Possu Huang Stanford University Other Ralf Schmidt Medical University of Vienna Gene and Cell Therapy Yoel Shiboleth TargetGene Biotechnologies LTD Gene and Cell Therapy Yossi Pollak ProtOS Nanomachines Ltd Gene and Cell Therapy Aaron Edwards KiraGen Bio Gene and Cell Therapy Beatrice Xuan Ho Agency for Science Technology and Research Gene and Cell Therapy Chayasith Uttamapinant Vidyasirimedhi Institute of Science and Technology Other Cobus Zwiegelaar Azargen Biotechnologies Plant Science Giuseppe Pugliese UNIMORE, University of Modena and Reggio Emilia Gene and Cell Therapy Isabel Chu Zipcode Bio Other Jennifer Clinton Baylor College of Medicine Vaccine Development Jiang-Hui Wang UMass Medical School (UMMS) Gene and Cell Therapy Lydia Lee University College London Cancer Institute Gene and Cell Therapy Markus Depfenhart North- West University, South Africa Vaccine Development Martin Janda University of South Bohemia České Budějovice Plant Science Matteo Dal Peraro University of the Witwatersrand Vaccine Development Matthew Daugherty University of California, San Diego (UCSD) Other Mihue Jang Korea Institute of Science and Technology Gene and Cell Therapy Muneaki Nakamura Ivy Natal Gene and Cell Therapy Munyaradzi Musvosvi University of Cape Town Vaccine Development Nigus Ambaye University of Maryland, Baltimore (UMB) Antibody Drug Discovery Olaf Piepenburg PartitionBio Ltd Other Pooja Kaur Ecole Polytechnique Fédérale de Lausanne (Switzerland) Antibody Drug Development Ramani Ramchandran Medical College of Wisconsin (MCW) Diagnostics Ramesh Babu Batchu Wayne State University Gene and Cell Therapy Rogelio Hernandez-Lopez Stanford University Gene and Cell Therapy Santanu Sasidharan UBC-Vancouver Antibody Drug Discovery Shoubao Ma City of Hope National Medical Center Gene and Cell Therapy Sreekumar Balan Icahn School of Medicine at Mount Sinai Antibody Drug Discovery Victoria McGilligan Ulster University Antibody Drug Discovery Volker Thiel University of Bern, Institut für Virologie und Immunologie(IVI) Other Wim Maes Katholieke Universiteit Leuven (KU Leuven) / PharmAbs Antibody Drug Discovery Xiaoyan Ding Klinikum der Universität MünchenRegion Gene and Cell Therapy Adam Thomas Burnet Institute Vaccine Development Andreas Stengl LMU Munich Munich, German Antibody Drug Discovery Behnam Rashidieh Mater Gene and Cell Therapy Chao Ma Cleveland Clinic Gene and Cell Therapy Cesare Cejas MFX Ltd Gene and Cell Therapy Christopher Batho University of Cambridge Gene and Cell Therapy Christopher J.

Vavricka Tokyo University of Agriculture and Technology Antibody Drug Discovery Coralie Werbrouck The University of Sydney Gene and Cell Therapy Emilie Stermann CNRS Antibody Drug Discovery Eric Shifrut Tel Aviv University Gene and Cell Therapy Ferenc Scheeren Leiden University Medical Center (LUMC) Antibody Drug Discovery Filipe Pinto i3S - Instituto de Investigação e Inovação da Universidade do Porto Others Jack Rudrum Massachusetts Institute of Technology Vaccine Development Jagannath Erisyon Inc. Others Jennifer Treweek University of Southern California Gene and Cell Therapy Jeremiah Kim UChicago Vaccine Development JoseGarrido Mesa Hospital 12 de Octubre Antibody Drug Discovery Jose Martinez-Navio University of Miami - Miller School of Medicine Gene and Cell Therapy Joshua Krueger University of Minnesota Gene and Cell Therapy Lay Khoon Too University of Sydney Gene and Cell Therapy Le Cong Stanford University Vaccine Development Neeraj Saini MD Anderson Cancer Center Gene and Cell Therapy Nicole Paulk Siren Biotechnology, Inc. Gene and Cell Therapy Patrick Holec Fletcher Biosciences Antibody Drug Discovery Pawel Stocki Ossianix Gene and Cell Therapy Shantanu Kumar Revision Bio Gene and Cell Therapy Sushama Telwatte University of Melbourne Gene and Cell Therapy Xiao Huang Drexel University Gene and Cell Therapy Xiaojing Gao Stanford Diagnostics Yoichi Furuya Pictor Ltd Diagnostics Bassel Akache National Research Council of Canada (NRC)Vaccine Development Bryan Bryson MIT/Ragon Institute Vaccine Development Chloe Christensen Children's Hospital Orange County Gene and Cell Therapy Christopher Lawrence Moore GentiBio Gene and Cell Therapy Diem TRAN Medical Genetics Institute Vaccine Development Fabio Mammano University of Padova, Dept.

of Physics and Astronomy Antibody Drug Discovery Ivan Loncarevic QUANTBIORES A/S (QBR) Vaccine Development Lajos Mates Biological Research Center, Szeged Others Liang Feng Duke University Gene and Cell Therapy Lucy Bartho The University of Melbourne Diagnostics Maider Zabala Ugalde Onena Medicines S. L.

Antibody Drug Discovery Miriam Longo Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico Milano, Lombardia Gene and Cell Therapy Naresha Saligrama Washington University in Saint Louis Others Natividad Garrido Mesa Kingston University Others Ori Zelichov ZipBio Inc. Others Reza Shahbazi Indiana University School of Medicine Gene and Cell Therapy Ritchie Chen University of California, San Francisco (UCSF) Gene and Cell Therapy Ryma Toumi Seattle Children's Research Institute Gene and Cell Therapy Sakthi Moorthy CCRM Gene and Cell Therapy Shimobi Onuoha Chimeris UK Ltd Gene and Cell Therapy Silvia gomez-sebastian Universidad Autonoma de Madrid Gene and Cell Therapy Torsten Meissner BIDMC Gene and Cell Therapy Tyler Renner Translational Biosciences Department, Human Health Therapeutics, National Research Council Others Uri Manor UCSD Gene and Cell Therapy William MacDonald RhoGen Inc. Antibody Drug Discovery Yijun Pan The University of Melbourne, Florey Department of Neuroscience and Mental Health Diagnostics Yoshinori Hasegawa KAZUSA DNA Research Institute Plant Science Yue Clare Lou Phase0, Inc. DBA Sift Biosciences Vaccine Development Zizhang Sheng Columbia University Irving Medical Center Antibody Drug Discovery Bomyoung Lee Fred Hutchinson Cancer Research Center (FHCRC) Gene and Cell Therapy Courtney Lane-Donovan University of California, San Francisco (UCSF) Diagnostics Edward Emmott University of Liverpool Diagnostics Enping Qu ClearVision Therapeutics, Inc Gene and Cell Therapy Jacob Brenner University of Pennsylvania Gene and Cell Therapy Jamie Cate University of California, Berkeley Antibody Drug Discovery Julian Reyes Vera Biotechnologies AI Drug Discovery Lennart Nickel Swiss Federal Institute of Technology Lausanne (EPFL) AI Drug Discovery Leyuan Ma University of Pennsylvania (UPenn) Vaccine Development Le Cong Stanford University Gene and Cell Therapy Maddie Williams Sift Biosciences Vaccine Development Monica Lisa Fernandez-Quintero Scripps Research Antibody Drug Discovery Nicole Pek Cincinnati Children's Hospital Medical Center (CCHMC) Gene and Cell Therapy Russell Vance UC Berkeley Vaccine Development Suki Albers-Fomenko Universität Hamburg Small Nucleic Acid Drug Timothy Riley 310 AI AI Drug Discovery Yonatan Lipsitz Lilium Therapeutics Inc (Labcentral) Gene and Cell Therapy Adam Creamer University of Oxford Diagnostics Alexandros Poulopoulos University of Maryland School of Medicine Gene and Cell Therapy Carter Palmer Third Element Bio Inc. AI Drug Discovery Craig Ramirez Tezcat Biosciences, Inc. Vaccine Development Davide Ferraris University of Eastern Piedmont (Novara, Italy) AI Drug Discovery Fabien Depis TregShield Bio Inc. Antibody Drug Discovery Hayley Bullen Burnet Institute Diagnostics Irina Spacova Laboratory of Applied Microbiology and Biotechnology (LAMB), University of Antwerp Vaccine Development Jakob Riccabona Institute of Drug Discovery, Leipzig University AI Drug Discovery Jianzhu Chen Koch Institute for Integrative Cancer Research at MIT, Massachusetts Institute of Technology AI Drug Discovery Laura Quinto Yale University Others Matthew Kan University of California, San Francisco and UC Berkeley Gene and Cell Therapy Pieter Van Wielendaele University of Antwerp, lab of Medical Biochemistry Antibody Drug Discovery Ramiro Perrotta Harvard Medical School (HMS) Gene and Cell Therapy Russel Vincent Macquarie University Gene and Cell Therapy Scott Ledger University of New South Wales (UNSW) Others Varun Shanker Stanford University AI Drug Discovery Vladimir Yarov-Yarovoy University of California, Davis (UC Davis) AI Drug Discovery Xiaojing Gao Stanford University Antibody Drug Discovery * What is the GenScript Life Science Research Grant Program?

The GenScript Life Science Research Grant (GenScript LSRG) is a global initiative for life science innovation. It provides funding, access to GenScript scientific expertise, and opportunities to connect with the broader research ecosystem. * What research areas does GenScript LSRG support?

The grant program supports researchers engaged in projects that can significantly contribute to critical areas of life science research, including, but not limited to, AI- drug discovery (AIDD), antibody development, cell and gene therapy, vaccines, diagnostics, and biologics.

In addition to the general research grant, GenScript LSRG also offers a special **AI Drug Discovery Frontier Grant** dedicated exclusively to projects focused on AI-driven drug discovery. * What is the application deadline? Applications close on October 5, 2026.

Applications submitted after the deadline may not be accepted for the 2026 program cycle. ### Application & Eligibility * How do I apply? Please submit your application through the official GenScript LSRG online application portal during the application window.

For the 2026 program, the application window is July 8 to October 5, 2026. * Do I need to register on GenScript. com to apply?

Applicants may directly apply by accessing the online application portal at https://www. genscript. com/grantprogram-form.

html. And this is the only way to apply for GenScript LSRG 2026 since it ensures fast and accurate processing of your application materials. * Can I submit my application through a Sales Representative?

No. Sales representatives can help share program information and answer general questions, but applications should be submitted through the official online application portal. * Who can apply? The program is open to researchers worldwide.

There are no restrictions on geographic location, and international applicants are encouraged to apply. Eligible applicants include academic/research institutions, universities, biotechnology companies, and other organizations engaged in life science research. Please note: Local, state, provincial, and government officials, as well as employees thereof, are not eligible.

Healthcare organizations (including hospitals, healthcare professionals, and their employees) may also be ineligible. * Can previous GenScript LSRG applicants or awardees apply again? Yes.

Previous applicants are welcome to reapply with a new or updated proposal. Previous GenScript LSRG award recipients may also apply for the 2026 program. However, prior funding or award status does not guarantee future selection.

All applications will be evaluated through the same review process and assessed based on scientific merit, innovation, feasibility, and potential impact. * Are postdoctoral fellows or scholars eligible to apply? We strongly encourage all eligible researchers, including PhD candidates, to apply as primary applicants.

To enhance the competitiveness of your proposal, you may consider involving your supervisor as a coinvestigator or advisor. * What does “only one application may be submitted per entity” mean? The entity refers to the laboratory or group under the direction of a specific principal investigator or involving the same investigator in a group.

Multiple independent principal investigators from the same institution may apply to the GenScript Life Science Research Grant Program. * Can I provide supporting materials? Supporting materials are optional and may be submitted through the application portal * What should be included in a strong application?

A strong application should clearly state the project objective, scientific rationale, innovation, feasibility, potential impact, proposed timeline, budget needs, and planned use of GenScript products or services. * How do I apply for the AI Drug Discovery Frontier Grant?

Applicants working on AI-enabled or AI-driven drug discovery should select AI Drug Discovery (AIDD) as the research area during application and provide a detailed project proposal and project budget breakdown, and clearly describe how GenScript services/products will be used to support the project. ### Funding, Services & Award Usage * Which GenScript services and products are eligible? All GenScript services are eligible for the grant.

Eligible catalog products include reagents and consumables such as CytoSinct Cell Isolation Nanobeads, Columns and Separators, Enceed T Cell Activation Reagent, antibody reagents, protein products (including cytokines and growth factors), PCR reagents, and electrophoresis gels.

The following products are **not eligible**: AmMag Quatro Maxi-Plasmid Purification and Mini-Plasmid Purification, AmMag SA Plus Semi-Automated System, eBlot, eStain, eZwest, electrophoresis gel tanks, and Catalog Stable Cell Lines. For more information, please contact LSRgrant@genscript. com * Can I use the award for salaries or services and reagents from other companies?

No. GenScript LSRG funding is earmarked for GenScript services and products. It is not intended for salaries or products/services from other companies. * Are GenScript LSRG awards provided as a credit?

Yes. the GenScript LSRG grant is awarded in the form of credits that can be used for services and products at GenScript. No cash or direct funds will be issued to awardees, in accordance with program policies.

* Is tax on services or material costs covered within the award budget? The cost associated with taxes for services and products is covered by the funds provided through the GenScript LSRG program. * Are shipping costs covered by the award funding?

No. Shipping costs are generally not included in GenScript LSRG award funding and will need to be covered separately by the awardee. * How long do awardees have to utilize the funding? Regarding the award timeframe, as we have significantly increased the funding levels for the 2026 program, the awards are intended to support both shorter-term and multi-year research projects.

* Once the award is granted, when is a project required to start? Projects are expected to commence within six months after receiving grant funding from GenScript. * My institution has contract pricing or a procurement partner.

Can I still apply? The grant value is applied based on GenScript standard list pricing. If selected as an awardee, we can work with you and the appropriate internal teams to determine the most suitable ordering process.

* I am not familiar with GenScript reagents and services. How can I prepare my budget? The GenScript LSRG is designed to support your research through GenScript services and product.

Even if you’ve never used GenScript services and products before, you are welcome to apply. We recommend visiting www. genscript.

com and exploring our dedicated Reagent Services pages to learn more about the platforms, technologies, and solutions we offer. These pages allow you to request quotes for specific services and connect directly with our experienced technical teams, ensuring you receive the most suitable support for your research needs.

As a global leader in biotechnology, GenScript has regional representatives who can provide one-on-one consultation to help you navigate service selection and budget planning. You can find your local representative via our Contact Us page. * How is my application evaluated?

Applications will be evaluated confidentially by an internal panel of experts. Review criteria include scientific merit, innovation, feasibility, potential impact, project timeline, and use of GenScript services and products. * Who evaluates my application?

GenScript has designated an internal committee dedicated to the grant evaluation process. All grant applications will be reviewed in a fully confidential manner. * How long is the review process?

Award announcements are expected within 10 weeks of submission deadline. * Can a Sales recommendation support an application? A Sales recommendation may provide additional context during internal review, but it does not guarantee selection.

Applicants should still submit a complete and strong application through the official portal. ### Confidentiality, IP & Contract * Who owns the intellectual property from work funded by GenScript LSRG? The awardee owns all rights to IP made in the performance of services and products under the GenScript LSRG program.

* What does the “Contract” as the last step of the grant application journey involve? To finalize the application procedure, the GenScript team will present a "collaboration agreement" for review by the grant recipients. Awardees will be asked to consent to allow GenScript and its partners to disseminate details about their research projects and affiliations for promotion and marketing purposes.

This will be in coordination with the investigators and according to publication schedules. Moreover, the contract will specify additional measures to recognize GenScript contributions in diverse forums publicly. Some examples include public posters or oral presentations, potential publications that employ data generated from the proposed project, co-author publications, webinars, and sponsored talks at international conferences.

* Can applicants review the collaboration agreement before submitting? The collaboration agreement will not be shared with applicants. Once funding decisions are made, the agreement will be made available to the award recipients.

The agreement gives investigators a lot of flexibility to decide how much they will engage in marketing activities with GenScript (e.g., webinars, presentations at events, developing case studies, etc.). ### Support & Troubleshooting * Who should I contact for more information? For any questions regarding the GenScript Life Science Research Grant Program, please contact us at LSRgrant@genscript.

com Our team will be happy to assist you. * Who should I contact if I have questions about my project budget? For any questions regarding the GenScript Life Science Research Grant Program, please contact us at LSRgrant@genscript.

com Our team will be happy to assist you. * Who should I contact to update my application information? For any questions regarding the GenScript Life Science Research Grant Program, please contact us at LSRgrant@genscript.

com Our team will be happy to assist you.